Company Description
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia.
Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.
The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
| Country | Switzerland |
| IPO Date | May 15, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 273 |
| CEO | Dr. Ameet Mallik M.B.A., M.S. |
Contact Details
Address: 13625 Technology Drive Eden Prairie, Minnesota 55344 United States | |
| Phone | 9529388080 |
| Website | adctherapeutics.com |
Stock Details
| Ticker Symbol | ADCT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0000061478 |
| CUSIP Number | H0036K147 |
| ISIN Number | CH0499880968 |
| Employer ID | 41-0743912 |
| SIC Code | 3661 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ameet Mallik M.B.A., M.S. | Chief Executive Officer and Director |
| Jose I. Carmona M.B.A. | Chief Financial Officer |
| Dr. Mohamed Zaki M.D., Ph.D. | Chief Medical Officer |
| Lisa Michelle Kallebo | Corporate Controller and Chief Accounting Officer |
| Dr. Michael Mulkerrin Ph.D. | Chief Technical Operations Officer |
| Dr. Patrick van Berkel Ph.D. | Chief Scientific Officer |
| Amanda Hamilton | Investor Relations Officer |
| Peter J. Graham Esq. | Chief Legal Officer |
| Eugenia Litz | Vice President of Investor Relations and Corporate Communications |
| Kimberly Pope | Senior Vice President and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2010 | 15-12G | Securities registration termination |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 16, 2010 | EFFECT | Notice of Effectiveness |
| Dec 10, 2010 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 9, 2010 | SC 14D9/A | Filing |
| Dec 9, 2010 | SC TO-T/A | Filing |
| Dec 9, 2010 | 25-NSE | Filing |
| Dec 9, 2010 | 8-K | Current Report |